ZebraTox Secures $250K in Pre-Seed Funding to Revolutionize Pre-Clinical Drug Testing

ZebraTox, a pioneering force in pre-clinical drug testing, is proud to announce a successful funding round that raised $250,000 to further advance its revolutionary high throughput toxicity screening platform in zebrafish. This innovative company is at the forefront of transforming the drug development landscape by implementing a patent-pending genotoxicity assay that uniquely integrates the cost effectiveness of traditional in vitro assays with the superior translatability of live vertebrate studies. By bridging these distinct approaches, ZebraTox is setting a new standard for toxicity screening, helping to reduce the risk of costly, late-stage drug failures while accelerating the development of life-saving therapeutics. The infusion of capital will be strategically applied to enhance platform scalability and refine the assay’s precision, ensuring that the technology not only remains at the cutting edge of toxicological science but also becomes increasingly accessible to pharmaceutical companies and researchers worldwide. With this funding boost, ZebraTox aims to expand its research and development capabilities, drive collaborations with industry partners, and ultimately streamline the drug development pipeline—a vital step in overcoming one of the most significant challenges in modern medicine. As the company continues to break new ground with its zebrafish-based screening approach, patients and healthcare providers alike stand to benefit from faster, more affordable toxicity testing that promises to reduce development timelines and improve the safety profile of new therapeutics. This milestone marks an exciting chapter in ZebraTox’s journey to transform drug safety evaluation and heralds a future where innovative science leads to tangible improvements in global health outcomes.